Of the 399 senior executives in the life sciences industry surveyed by the Economist Intelligence Unit (EIU) recently, 64% of respondents said that demonstrating value is a key challenge facing their business. The major issue, most agree, is that stakeholders have different perceptions of what value is.
Of the 399 senior executives in the life sciences industry surveyed by the Economist Intelligence Unit (EIU) recently, 64% of respondents said that demonstrating value is a key challenge facing their business. The major issue, most agree, is that stakeholders have different perceptions of what value is.
The Quintiles-sponsored report, Reinventing Biopharma, found that most pharma companies have made at least one change to their business model, commercial and/or R&D strategy to meet this ‘value challenge’; many are accepting that the demand to provide value has had an important or significant impact on their business model and are “coordinating the response to the challenge across the company”.
Dr Adrian Thomas, VP for Market Access at Janssen, for example, said that the company’s R&D organization has developed a “fairly solid understanding of payer value”. He explained: “Clinical evidence and regulatory hurdles are still crucial, but equally important are commercial considerations that products will meet other thresholds of acceptability…We have the value question as a critical piece of decision making. That is a huge departure from three to five years ago.”
But there remains little convergence in dealing with the value question; no single strategy is emerging as a majority favourite. As Dr Ed Pezalla of Aetna comments, while many players are aware of the issue, “substantial change still has to take place”.
Until then, demonstrating value will very much remain a challenge for the industry.
Reinventing Biopharma: the value challenge, is available here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.